ReviewImmunological reviews2009
The tyrosine kinase network regulating mast cell activation.
Review in Immunological reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 431 citations in OpenAlex.
- Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.Lancet (London, England) · 2017Trial
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Article
- Emerging Therapies for Anaphylaxis.Immunology and allergy clinics of North America · 2026Review
- Role of Src family kinases Fyn and Lyn in arenavirus infection.Journal of virology · 2026Article
- Pluviatolide Attenuates Type I Hypersensitivity through Regulation of Mast Cell Activation.Biomolecules & therapeutics · 2026Article
- The Gut Microbiota-Mast Cell Axis in Intestinal Homeostasis and Food Allergy Pathogenesis.Biomolecules · 2026Review
- Mitochondrial subtypes in renal ischemia reperfusion injury guide delayed graft function and Long-Term graft prediction.Scientific reports · 2025Article
- Rilzabrutinib for the Treatment of Immune Thrombocytopenia.European journal of haematology · 2025Review
- Effects ofPreventive nutrition and food science · 2025Article
- KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE-mediated Activation.European journal of immunology · 2025Article
- SHIP-1 Differentially Regulates IgE-Induced IL-10 and Antiviral Responses in Human Monocytes.European journal of immunology · 2025Article
- Enhancing allergy diagnosis: mass spectrometry as a complementary technique to the basophil activation test.Frontiers in allergy · 2025Review
- Unique compound with anti-allergic action: inhibition of Lyn kinase activity by KIRA6.Frontiers in pharmacology · 2025Article
- c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer's disease.Life science alliance · 2024Article
- Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.Immune network · 2024Review
- Integrated-omics analysis with explainable deep networks on pathobiology of infant bronchiolitis.NPJ systems biology and applications · 2024Article
- Radiocontrast medium induces histamine release in association with upregulation of miR‑19a‑3p and miR‑362‑3p expression.Biomedical reports · 2024Article
- Mechanobiology of Type 1 hypersensitivity: Elucidating the impacts of mechanical forces in allergic reactions.Mechanobiology in medicine · 2024Review
- Bioactivity-Guided Fraction from Viscera of Abalone,Journal of microbiology and biotechnology · 2024Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Mast cell mediator release represents a pivotal event in the initiation of inflammatory reactions associated with allergic disorders. These responses follow antigen-mediated aggregation of immunoglobulin E (IgE)-occupied high-affinity receptors for IgE (Fc epsilon RI) on the mast cell surface, a response which can be further enhanced following stem cell factor-induced ligation of the mast cell growth factor receptor KIT (CD117). Activation of tyrosine kinases is central to the ability of both Fc epsilon RI and KIT to transmit downstream signaling events required for the regulation of mast cell activation. Whereas KIT possesses inherent tyrosine kinase activity, Fc epsilon RI requires the recruitment of Src family tyrosine kinases and Syk to control the early receptor-proximal signaling events. The signaling pathways propagated by these tyrosine kinases can be further upregulated by the Tec kinase Bruton's tyrosine kinase and downregulated by the actions of the tyrosine Src homology 2 domain-containing phosphatase 1 (SHP-1) and SHP-2. In this review, we discuss the regulation and role of specific members of this tyrosine kinase network in KIT and Fc epsilon RI-mediated mast cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.